In line with increased investor demand the DDF team will grow, including the appointment of a Chief Executive to lead the organisation.For further information please visit the DDF website at Dementia Discovery Fund Laurence Barker, CBO, [email protected], 44 20 7421 7094 Consilium Strategic Communications Mary-Jane Elliott, Chris Gardner, Ivar Milligan, Melissa Gardiner [email protected] 20 3709 5700 About the Dementia Discovery Fund (DDF) The DDF is a venture capital fund which invests in projects and companies to discover and develop novel, effective disease-modifying therapeutics for dementia.
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings.
It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started.
The DDF is uniquely positioned to benefit from the expertise of its world-class Scientific Advisory Board (SAB) which includes heads of Neuroscience and/or R&D from seven major pharma companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda) and ARUK, who collectively have a large network and experience in neuroscience drug discovery.
The SAB provides ongoing advice and knowledge, offers insights on different approaches and historical failures, suggests priority areas to explore new approaches to treat dementia and advises on strategies to drugging these new pathways.
Since its launch in October 2015, the DDF has made significant progress building an initial portfolio of 12 investments in drug discovery companies and projects predominantly in the UK and US in areas including microglial biology and inflammation, mitochondrial dynamics, trafficking and membrane biology and synaptic physiology and function.
The DDF team believes there is a significant opportunity to develop dementia drugs targeting biological pathways beyond the prevailing amyloid beta hypothesis and to apply insights from areas such as oncology and immunology to develop novel drugs targeting these other biological pathways that may drive different forms of dementia.
added: “We believe the DDF’s novel model presents a real opportunity to improve the treatment of neurological diseases, and, importantly for us, provide valuable insights into neurodegenerative disorders which have been associated with our sport.
Our investment fits with our strategy of supporting research into new ways to diagnose, treat and prevent common injuries in current and retired NFL players which has included previously supporting projects to slow and reverse the accumulation of Tau protein in the brain which leads to CTE.” The NFLPA investment into the DDF follows a recent m investment by Bill Gates and represents further US interest in the fund, reflecting the global importance of developing new treatments for dementia.
To be considered for a one-on-one meeting, please complete a short application through the links below: New York – December 13, 2017: https:// Cambridge, MA – January 23, 2018: https:// Latest Posts – Broad range of novel approaches to develop disease modifying dementia drugs – London, 13 November 2017 – The Dementia Discovery Fund (DDF) today announces a million investment from Bill Gates.